NCT03791398 - BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

June 16, 2021

Study Completion Date

August 5, 2021

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Dose level 1 ONC201 625mg

ONC201 625mg + Nivolumab 240mg IV flat dose

DRUG

Dose level 2 ONC201 500mg

ONC201 500mg + Nivolumab 240mg IV flat dose

DRUG

Dose level 3 ONC201 375mg

ONC201 375mg + Nivolumab 240mg IV flat dose

Trial Locations (1)

Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals, Providence